Global Information
회사소개 | 문의 | 비교리스트

세계의 정밀의료 시장(2020-2030년)

Global Precision Medicine Market: Focus on Ecosystem, Technology, Application, Country Data (21 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030

리서치사 BIS Research Inc.
발행일 2020년 09월 상품 코드 959513
페이지 정보 영문
가격
US $ 7,000 ₩ 8,226,000 Unprintable PDF (Single User License)
US $ 7,500 ₩ 8,814,000 Hard Copy
US $ 9,000 ₩ 10,576,000 Printable PDF (Single Site License)
US $ 11,000 ₩ 12,927,000 Printable PDF and Excel (Enterprise-wide License)


세계의 정밀의료 시장(2020-2030년) Global Precision Medicine Market: Focus on Ecosystem, Technology, Application, Country Data (21 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030
발행일 : 2020년 09월 페이지 정보 : 영문

세계 정밀의료 시장 규모는 2030년 2,786억 1,000만 달러 규모로 성장할 것으로 예측됩니다. 개인 건강 관리에 대한 의식 고양, 스마트폰 및 태블릿 등 스마트 기기의 의료로의 통합, 정밀진단 툴 개발을 위한 IT 기업과의 제휴 및 합의 확대 등의 요인이 시장 성장을 가속화하고 있습니다.

세계의 정밀의료(Precision Medicine) 시장을 조사했으며, 시장의 정의와 개요, 코로나19(COVID-19) 및 기타 시장 영향요인 분석, 주요 이니셔티브와 프로그램, 규제 프레임워크, 파이프라인 동향, 시장 규모 추이와 예측, 에코시스템·용도·지역/주요 국가 등 각종 구분별 분석, 경쟁 환경, 주요 기업 개요 등의 정보를 정리했습니다.

제1장 제품 정의

제2장 조사 범위

제3장 조사 방법

제4장 시장 개요

  • 시장의 정의
  • 정밀의료 : 환자중심 의학의 개척자
  • 정밀의료 : 맞춤형 치료를 위한 One-Size-Fits-All 이론의 개조
  • 이니셔티브 및 프로그램
  • 정밀의료 : 구현 기술과 용도
  • 코로나19(COVID-19)의 영향

제5장 시장 역학

  • 개요
  • 성장 촉진요인
  • 성장 저해요인
  • 시장 기회

제6장 산업 인사이트

  • 특허 분석
  • 법적 요건과 규제
  • 파이프라인 분석
  • 법적 요건과 프레임워크 : FDA
  • 법적 요건과 프레임워크 : EMA
  • 법적 요건과 프레임워크 : MHLW

제7장 경쟁 구도

  • 시너지 활동
  • 시장 점유율 분석

제8장 시장 분석·예측 : 에코시스템별

  • 개요
  • 응용 과학
    • 게노믹스
    • 약물유전체학
    • 기타
  • 정밀진단
    • 분자진단(MDx)
    • 의료영상 처리
  • 디지털 헬스·IT
  • 정밀치료

제9장 시장 분석·예측 : 용도별

  • 개요
  • 종양
  • 감염증
  • 신경
  • 심혈관
  • 생활습관병/내분비계
  • 소화기계
  • 기타

제10장 시장 분석·예측 : 지역/주요 국가별

  • 개요
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 기타 지역

제11장 기업 개요

  • Abbott Laboratories
  • Almac Group Ltd.
  • Amgen Inc.
  • ANGLE plc
  • Astellas Pharma Inc.
  • Astra Zeneca
  • ASURAGEN INC.
  • Bio-Rad Laboratories, Inc.
  • bioMerieux S.A.
  • Bristol-Myers Squibb Company
  • Cardiff Oncology
  • CETICS Healthcare Technologies GmbH
  • Danaher Corporation
  • Eli Lilly and Company Limited
  • Epic Sciences, Inc.
  • F. Hoffmann-La Roche Ltd
  • General Electric Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Illumina, Inc.
  • Intomics A/S
  • Johnson & Johnson Services, Inc.
  • Konica Minolta, Inc.
  • Laboratory Corporation of America Holdings
  • MDx Health, Inc.
  • Menarini Silicon Biosystems, Inc.
  • Merck KGaA
  • Myriad Genetics, Inc.
  • Novartis AG
  • Oracle Corporation.
  • Pacific Biosciences of California, Inc.
  • Partek, Inc.
  • Pfizer Inc.
  • QIAGEN N.V.*
  • Quest Diagnostics Incorporated
  • Randox Laboratories Ltd.
  • Sanofi S.A.
  • Sysmex Corporation
  • Teva Pharmaceuticals Industries Ltd.
  • Thermo Fisher Scientific Inc.
LSH 20.09.11

List of Figures

  • Figure 1: Precision Medicine: Treatment Tailored to an Individual's Genetic Structure
  • Figure 2: Precision Medicine - a Multi-Faceted Approach to Patient Care
  • Figure 3: Decreasing Cost and Increasing Output (TB) of Genome Sequencing (2009-2025)
  • Figure 4: Impact Analysis of Market Drivers and Market Challenges on the Global Precision Medicine Market
  • Figure 5: Global Precision Medicine Market (by Ecosystem), 2019 vs. 2030 ($Billion)
  • Figure 6: Global Precision Medicine Market (by Application Area), 2019 vs. 2030 ($Billion)
  • Figure 7: Global Precision Medicine Market (by Region) Snapshot
  • Figure 1.1: Global Precision Medicine Market Segmentation
  • Figure 1.2: Global Precision Medicine Market Methodology
  • Figure 3.1: Primary Research Methodology
  • Figure 3.2: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 4.1: Precision Medicine Approach
  • Figure 4.2: Evolution of Precision Medicine Technology
  • Figure 4.3: Precision Medicine: Enabling Technologies and Applications
  • Figure 4.4: Structured Big Data Reporting Benefits
  • Figure 4.5: Generalized Process for the Microarray
  • Figure 4.6: Global Precision Medicine Market: COVID-19 Impact
  • Figure 5.1: Impact Analysis
  • Figure 5.2: Percent of Patients Whose Tumor Were Driven by Certain Genetic Mutations That Could Be Targets for Specific Drugs
  • Figure 6.1: Patent Analysis
  • Figure 6.2: Role of FDA in Advancing Precision Medicine
  • Figure 6.3: FDA Guidelines for CDx Approval
  • Figure 7.1: Share of Key Developments and Strategies, January 2012-July 2020
  • Figure 7.2: Synergistic Activities (January 2012- July 2020)
  • Figure 7.3: Product launches, Enhancements, and Upgradation by Companies (January 2012-July 2020)
  • Figure 7.4: Product Approvals by Companies (January 2012-July 2020)
  • Figure 7.5: Merger and Acquisitions Share by Companies (January 2012-July 2020)
  • Figure 7.6: Business Expansion Share by Companies (January 2012-July 2020)
  • Figure 7.7: Market Share Analysis for PM Applied Sciences Ecosystem, 2019
  • Figure 7.8: Market Share Analysis for PM Diagnostics Ecosystem, 2019
  • Figure 7.9: Market Share Analysis by PM Therapeutics Ecosystem, 2019
  • Figure 7.10: Market Share Analysis by PM Digital Health and IT Ecosystem, 2019
  • Figure 7.11: Share of Key Developments and Strategies, January 2014-February 2020
  • Figure 8.1: Precision Medicine: The Ecosystem
  • Figure 8.2: Global Precision Medicine Market (by Ecosystem)
  • Figure 8.3: Global Precision Medicine Market (by Ecosystem), 2019-2030
  • Figure 8.4: Global Precision Medicine Market (by Applied Sciences)
  • Figure 8.5: Global Precision Medicine Market (by Applied Sciences), 2019-2030
  • Figure 8.6: Precision Medicine: Multi-omics Sciences
  • Figure 8.7: Global Precision Medicine Applied Sciences Market (by Type), 2019-2030
  • Figure 8.8: Precision Medicine: Genomics
  • Figure 8.9: Global Precision Medicine Genomics Market, 2019-2030
  • Figure 8.10: Global Precision Medicine Genomics Market (by Technology), 2019-2030
  • Figure 8.11: Global Precision Medicine PCR Market, 2019-2030
  • Figure 8.12: Global Precision Medicine PCR Market (by Product ), 2019-2030
  • Figure 8.13: Global Precision Medicine PCR Market (by End User), 2019-2030
  • Figure 8.14: Global Precision Medicine PCR Market (by Region), 2019-2030
  • Figure 8.15: Evolution of Next-Generation Sequencing
  • Figure 8.16: Global Precision Medicine NGS Market, 2019-2030
  • Figure 8.17: Global Precision Medicine NGS Market (by Product), 2019-2030
  • Figure 8.18: Global Precision Medicine NGS Market (by Technology), 2019-2030
  • Figure 8.19: Global Precision Medicine NGS Market (by End User), 2019-2030
  • Figure 8.20: Global Precision Medicine NGS Market (by Region), 2019-2030
  • Figure 8.21: Global Precision Medicine Genome Editing Market, 2019-2030
  • Figure 8.22: Global Precision Medicine Genome Editing Market (by Product), 2019-2030
  • Figure 8.23: Global Precision Medicine Genome Editing Market (by End User), 2019-2030
  • Figure 8.24: Global Precision Medicine Genome Editing Market (by Region), 2019-2030
  • Figure 8.25: Global Precision Medicine Other Technologies Market, 2019-2030
  • Figure 8.26: Global Precision Medicine Other Technologies Market (by Region), 2019-2030
  • Figure 8.27: Role of Biomarkers in Pharmacogenomics
  • Figure 8.28: Role of FDA In Pharmacogenomics
  • Figure 8.29: Global Precision Medicine Pharmacogenomics Market, 2019-2030
  • Figure 8.30: Global Precision Medicine Pharmacogenomics Market (by Pharmacogenomics Services), 2019-2030
  • Figure 8.31: Global Precision Medicine Pharmacogenomics Market (by End User), 2019-2030
  • Figure 8.32: Global Precision Medicine Pharmacogenomics Market (by Region), 2019-2030
  • Figure 8.33: Global Precision Medicine Other Applied Sciences Market, 2019-2030
  • Figure 8.34: Precision Medicine: Diagnostics
  • Figure 8.35: Global Precision Medicine Market (by Precision Diagnostics)
  • Figure 8.36: Global Precision Medicine Market (by Precision Diagnostics), 2019-2030
  • Figure 8.37: Global Precision Medicine Diagnostics Market (by Type), 2019-2030
  • Figure 8.38: General Workflow of a Molecular Diagnostic Assay
  • Figure 8.39: Global Precision Medicine Diagnostics Market (by Molecular Diagnostics)
  • Figure 8.40: Global Precision Medicine Molecular Diagnostics Market, 2019-2030
  • Figure 8.41: Global Precision Medicine Molecular Diagnostics Market (by Type), 2019-2030
  • Figure 8.42: Benefits and Risks Associated with NIPT
  • Figure 8.43: Global Precision Medicine NIPT Market, 2019-2030
  • Figure 8.44: Global Precision Medicine NIPT Market (by Platform), 2019-2030
  • Figure 8.45: Global Precision Medicine NIPT Market (by Region), 2019-2030
  • Figure 8.46: Drug and Companion Diagnostics Development Process
  • Figure 8.47: Benefits and Risks Associated with Companion Diagnostics
  • Figure 8.48: Global Precision Medicine Companion Diagnostics Market, 2019-2030
  • Figure 8.49: Global Precision Medicine Companion Diagnostics Market (by Technology), 2019-2030
  • Figure 8.50: Global Precision Medicine Companion Diagnostics Market (by Indication), 2019-2030
  • Figure 8.51: Global Precision Medicine Companion Diagnostics Market (by Region), 2019-2030
  • Figure 8.52: Clinical Applications of Liquid Biopsy
  • Figure 8.53: Global Precision Medicine Liquid Biopsy Market, 2019-2030
  • Figure 8.54: Global Precision Medicine Liquid Biopsy Market (by Indication), 2019-2030
  • Figure 8.55: Global Precision Medicine Liquid Biopsy Market (by Region), 2019-2030
  • Figure 8.56: Global Precision Medicine Other Molecular Diagnostics Market, 2020-2030
  • Figure 8.57: Global Precision Medicine Other Molecular Diagnostics Market (by Type), 2019-2030
  • Figure 8.58: Global Precision Medicine Other Molecular Diagnostics Market (by Region), 2019-2030
  • Figure 8.59: Global Precision Medicine Medical Imaging Market, 2019-2030
  • Figure 8.60: Global Precision Medicine Medical Imaging Market (by Type), 2019-2030
  • Figure 8.61: Global Precision Medicine Imaging Analytics Market, 2019-2030
  • Figure 8.62: Global Precision Medicine CADx Market, 2019-2030
  • Figure 8.63: Global Precision Medicine Medical Imaging Market (by Region), 2019-2030
  • Figure 8.64: Global Precision Medicine Digital Health and Information Technology Market, 2019-2030
  • Figure 8.65: Global Precision Medicine Digital Health and Information Technology Market (by Type), 2019-2030
  • Figure 8.66: Global Precision Medicine CDSS Market, 2019-2030
  • Figure 8.67: Big Data Attributes
  • Figure 8.68: Global Precision Medicine Big Data Analytics Market, 2019-2030
  • Figure 8.69: Big Data Analytics: Key Benefits
  • Figure 8.70: Global Precision Medicine IT Infrastructure Market, 2019-2030
  • Figure 8.71: Global Precision Medicine IT Infrastructure Market (by Type), 2019-2030
  • Figure 8.72: Global Precision Medicine Genomics Informatics Market, 2019-2030
  • Figure 8.73: Global Precision Medicine Genomics Informatics Market (by Product Type), 2019-2030
  • Figure 8.74: Global Precision Medicine In-Silico Informatics Market, 2019-2030
  • Figure 8.75: Global Precision Medicine Mobile Health Market, 2019-2030
  • Figure 8.76: Global Precision Medicine Digital Health and Information Technology Market (by End User), 2019-2030
  • Figure 8.77: Global Precision Medicine Digital Health and Information Technology Market (by Region), 2019-2030
  • Figure 8.78: Global Precision Medicine Therapeutics Market, 2019-2030
  • Figure 8.79: Global Precision Medicine Therapeutics Market (by Type), 2019-2030
  • Figure 8.80: Global Precision Medicine Clinical Trials Market, 2019-2030
  • Figure 8.81: Global Precision Medicine Clinical Trials Market (by Region), 2019-2030
  • Figure 8.82: Types of Cell Therapy
  • Figure 8.83: Global Precision Medicine Cell Therapy Market, 2019-2030
  • Figure 8.84: Global Precision Medicine Cell Therapy Market (by Region), 2019-2030
  • Figure 8.85: Global Precision Medicine Drug Discovery and Research Market, 2019-2030
  • Figure 8.86: Global Precision Medicine Drug Discovery and Research Market (by Region), 2019-2030
  • Figure 8.87: Types of Gene Therapy
  • Figure 8.88: Types of Gene Therapy
  • Figure 8.89: Global Precision Medicine Gene Therapy Market, 2019-2030
  • Figure 8.90: Global Precision Medicine Drug Discovery and Research Market (by Region), 2019-2030
  • Figure 9.1: Global Precision Medicine Applications Market, 2019-2030
  • Figure 9.2: Types of Cancer
  • Figure 9.3: Global Precision Medicine Oncology Market, 2019-2030
  • Figure 9.4: Global Precision Medicine Infectious Diseases Market, 2019-2030
  • Figure 9.5: Number of Deaths by Top 18 Infectious Diseases, 2018
  • Figure 9.6: Global Precision Medicine Neurology Market, 2019-2030
  • Figure 9.7: Global Precision Medicine Cardiovascular Market, 2019-2030
  • Figure 9.8: Global Precision Medicine Lifestyle and Endocrinology Market, 2019-2030
  • Figure 9.9: Global Precision Medicine Gastroenterology Market, 2019-2030
  • Figure 9.10: Global Precision Medicine Other Applications Market, 2019-2030
  • Figure 10.1: Global Precision Medicine Market (by Region), 2019 and 2030
  • Figure 10.2: Global Precision Medicine Market (by Region), 2019-2030
  • Figure 10.3: North America Precision Medicine Market, 2019-2030
  • Figure 10.4: North America: Market Dynamics
  • Figure 10.5: North America Precision Medicine Market (by Ecosystem), 2019-2030
  • Figure 10.6: North America Precision Medicine Market (by Country), 2019-2030
  • Figure 10.7: U.S. Precision Medicine Market, 2019-2030
  • Figure 10.9: Europe Precision Medicine Market, 2019-2030
  • Figure 10.10: Europe: Market Dynamics
  • Figure 10.11: Europe Precision Medicine Market (by Ecosystem), 2019-2030
  • Figure 10.12: Europe Precision Medicine Market (by Country), 2019-2030
  • Figure 10.13: Germany Precision Medicine Market, 2019-2030
  • Figure 10.14: France Precision Medicine Market, 2019-2030
  • Figure 10.15: Italy Precision Medicine Market, 2019-2030
  • Figure 10.16: The U.K. Precision Medicine Market, 2019-2030
  • Figure 10.17: Spain Precision Medicine Market, 2019-2030
  • Figure 10.18: Rest-of-Europe Precision Medicine Market, 2019-2030
  • Figure 10.19: Asia-Pacific Precision Medicine Market, 2019-2030
  • Figure 10.20: APAC: Market Dynamics
  • Figure 10.21: Asia-Pacific Precision Medicine Market (by Ecosystem), 2019-2030
  • Figure 10.22: Asia-Pacific Precision Medicine Market (by Country), 2019-2030
  • Figure 10.23: China Precision Medicine Market, 2019-2030
  • Figure 10.24: Japan Precision Medicine Market, 2019-2030
  • Figure 10.25: Australia Precision Medicine Market, 2019-2030
  • Figure 10.26: India Precision Medicine Market, 2019-2030
  • Figure 10.27: Rest-of-Asia-Pacific Precision Medicine Market, 2019-2030
  • Figure 10.28: Latin America Precision Medicine Market, 2019-2030
  • Figure 10.29: APAC: Market Dynamics
  • Figure 10.30: Latin America Precision Medicine Market (by Ecosystem), 2019-2030
  • Figure 10.31: Latin America Precision Medicine Market (by Country), 2019-2030
  • Figure 10.32: Brazil Precision Medicine Market, 2019-2030
  • Figure 10.33: Mexico Precision Medicine Market, 2019-2030
  • Figure 10.34: Rest-of-Latin America Precision Medicine Market, 2019-2030
  • Figure 10.35: Rest-of-the-World Precision Medicine Market (by Ecosystem), 2019-2030
  • Figure 10.36: Rest-of-the-World Precision Medicine Market, 2019-2030
  • Figure 11.1: Total Number of Companies Profiled
  • Figure 11.2: Abbott Laboratories: Product Portfolio
  • Figure 11.3: Abbott Laboratories: Overall Financials, 2017-2019
  • Figure 11.4: Abbott Laboratories: Revenue (by Segment), 2017-2019
  • Figure 11.5: Abbott Laboratories: Revenue (by Region), 2017-2019
  • Figure 11.6: Abbott Laboratories: R&D Expenditure, 2017-2019
  • Figure 11.7: Abbott Laboratories: SWOT Analysis
  • Figure 11.8: Almac Group Ltd.: SWOT Analysis
  • Figure 11.9: Abbott Laboratories: Product Portfolio
  • Figure 11.10: Amgen Inc.: Overall Financials, 2017-2019
  • Figure 11.11: Amgen Inc.: Revenue (by Region), 2018-2019
  • Figure 11.12: Amgen Inc. R&D Expenditure, 2017-2019
  • Figure 11.13: Amgen Inc.: SWOT Analysis
  • Figure 11.14: ANGLE plc: Overall Financials, 2017-2019
  • Figure 11.15: ANGLE plc: Revenue (by Region), 2018-2019
  • Figure 11.16: ANGLE plc R&D Expenditure, 2017-2019
  • Figure 11.17: ANGLE plc: SWOT Analysis
  • Figure 11.18: Astellas Pharma Inc.: Product Portfolio
  • Figure 11.19: Astellas Pharma Inc.: Overall Financials, 2017-2019
  • Figure 11.20: Astellas Pharma Inc. R&D Expenditure, 2017-2019
  • Figure 11.21: Astellas Pharma Inc.: SWOT Analysis
  • Figure 11.22: Astra Zeneca: Product Portfolio
  • Figure 11.23: Astra Zeneca: Overall Financials, 2017-2019
  • Figure 11.24: Astra Zeneca: Revenue (by Business Segment), 2017-2019
  • Figure 11.25: Astra Zeneca: Revenue (by Region), 2017-2019
  • Figure 11.26: Astra Zeneca: SWOT Analysis
  • Figure 11.27: ASURAGEN INC.: SWOT Analysis
  • Figure 11.28: Bio-Rad Laboratories, Inc: Overall Financials, 2017-2019
  • Figure 11.29: Bio-Rad Laboratories, Inc: Revenue (by Business Segment), 2017-2019
  • Figure 11.30: Bio-Rad Laboratories, Inc: Revenue (by Region), 2017-2019
  • Figure 11.31: Bio-Rad Laboratories, Inc. R&D Expenditure, 2014-2017
  • Figure 11.32: Bio-Rad Laboratories, Inc: SWOT Analysis
  • Figure 11.33: bioMérieux S.A.: Product Portfolio
  • Figure 11.34: bioMérieux S.A.: Overall Financials, 2017-2019
  • Figure 11.35: bioMérieux S.A.: Revenue (by Segment), 2017-2019
  • Figure 11.36: bioMérieux S.A.: Revenue (by Region), 2018-2019
  • Figure 11.37: bioMérieux S.A.: SWOT Analysis
  • Figure 11.38: Bristol-Myers Squibb Company: Product Portfolio
  • Figure 11.39: Bristol-Myers Squibb Company: Overall Financials, 2017-2019
  • Figure 11.40: Bristol-Myers Squibb Company R&D Expenditure, 2015-2017
  • Figure 11.41: Bristol-Myers Squibb Company.: SWOT Analysis
  • Figure 11.42: Cardiff Oncology.: Product Portfolio
  • Figure 11.43: Cardiff Oncology: Overall Financials, 2018-2019
  • Figure 11.44: Cardiff Oncology: R&D Expenditure, 2018-2019
  • Figure 11.45: Cardiff Oncology: SWOT Analysis
  • Figure 11.46: CETICS Healthcare Technologies GmbH: SWOT Analysis
  • Figure 11.47: Danaher Corporation: Overall Financials, 2017-2019
  • Figure 11.48: Danaher Corporation: Revenue (by Business Segment), 2017-2019
  • Figure 11.49: Danaher Corporation: SWOT Analysis
  • Figure 11.50: Eli Lilly and Company Limited: Product Portfolio
  • Figure 11.51: Eli Lilly and Company Limited: Overall Financials, 2017-2019
  • Figure 11.52: Eli Lilly and Company Limited: Revenue (by Region), 2018-2019
  • Figure 11.53: Eli Lilly and Company Limited: SWOT Analysis
  • Figure 11.54: Epic Sciences, Inc.: Product Portfolio
  • Figure 11.55: Epic Sciences, Inc.: SWOT Analysis
  • Figure 11.56: F. Hoffmann-La Roche Ltd: Product Portfolio
  • Figure 11.57: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
  • Figure 11.58: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2017-2019
  • Figure 11.59: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019
  • Figure 11.60: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
  • Figure 11.61: F. Hoffmann-La Roche Ltd: SWOT Analysis
  • Figure 11.62: GE Healthcare: Product Portfolio
  • Figure 11.63: General Electric Company: Overall Financials, 2017-2019
  • Figure 11.64: General Electric Company: Revenue Split for Healthcare, 2017-2019
  • Figure 11.65: General Electric: Healthcare Revenue (by Region), 2017-2019
  • Figure 11.66: General Electric Company: R&D Expenditure, 2017-2019
  • Figure 11.67: General Electric Company: SWOT Analysis
  • Figure 11.68: Gilead Sciences, Inc.: Product Portfolio
  • Figure 11.69: Gilead Science, Inc.: SWOT Analysis
  • Figure 11.70: GlaxoSmithKline plc: Overall Financials, 2017-2019
  • Figure 11.71: GlaxoSmithKline plc: Revenue (by Segment), 2017-2019
  • Figure 11.72: GlaxoSmithKline plc: Revenue (by Region), 2017-2019
  • Figure 11.73: GlaxoSmithKline plc: R&D Expenditure, 2017-2019
  • Figure 11.74: GlaxoSmithKline plc: SWOT Analysis
  • Figure 11.75: Illumina, Inc.: Product Portfolio
  • Figure 11.76: Illumina, Inc.: Overall Financials, 2017-2019
  • Figure 11.77: Illumina, Inc.: Revenue (by Segment), 2017-2019
  • Figure 11.78: Illumina, Inc.: Revenue (by Region), 2017-2019
  • Figure 11.79: Illumina, Inc.: R&D Expenditure, 2017-2019
  • Figure 11.80: Illumina, Inc.: SWOT Analysis
  • Figure 11.81: Intomics A/S: SWOT Analysis
  • Figure 11.82: Illumina, Inc.: Product Portfolio
  • Figure 11.83: Johnson & Johnson Services, Inc. Company: Overall Financials, 2017-2019
  • Figure 11.84: Johnson & Johnson Services, Inc. Company: R&D Expenditure, 2017-2019
  • Figure 11.85: Johnson & Johnson Services, Inc.: SWOT Analysis
  • Figure 11.86: Konica Minolta, Inc.: Overall Financials, 2017-2019
  • Figure 11.87: Konica Minolta, Inc.: Revenue (by Region), 2017-2019
  • Figure 11.88: Konica Minolta, Inc.: SWOT Analysis
  • Figure 11.89: Laboratory Corporation of America Holdings: Overall Financials, 2017-2019
  • Figure 11.90: Laboratory Corporation of America Holdings: Revenue (by Segment), 2017-2019
  • Figure 11.91: Laboratory Corporation of America Holdings: Revenue (by Region), 2019
  • Figure 11.92: Laboratory Corporation of America Holdings: SWOT Analysis
  • Figure 11.93: MDx Health, Inc.: Overall Financials, 2017--2019
  • Figure 11.94: MDx Health, Inc.: SWOT Analysis
  • Figure 11.95: Menarini Silicon Biosystems, Inc.: SWOT Analysis
  • Figure 11.96: Merck KGaA: Product Portfolio
  • Figure 11.97: Merck KGaA: Overall Financials, 2017-2019
  • Figure 11.98: Merck KGaA: Revenue (by Segment), 2017-2019
  • Figure 11.99: Merck KGaA: Revenue (by Region), 2017-2019
  • Figure 11.100: Merck KGaA: Life Science Segment Revenue (by Region), 2017-2019
  • Figure 11.101: Merck KGaA: R&D Expenditure, 2017-2019
  • Figure 11.102: Merck KGaA: SWOT Analysis
  • Figure 11.103: Myriad Genetics, Inc.: Product Portfolio
  • Figure 11.104: Myriad Genetics, Inc.: Overall Financials, 2017-2019
  • Figure 11.105: Myriad Genetics, Inc.: Revenue (by Business Segment), 2017-2019
  • Figure 11.106: Myriad Genetics, Inc.: R&D Expenditure, 2017-2019
  • Figure 11.107: Myriad Genetics, Inc.: SWOT Analysis
  • Figure 11.108: Novartis AG: Overall Product Portfolio
  • Figure 11.109: Novartis AG: Overall Financials, 2017-2019
  • Figure 11.110: Novartis AG Net Revenue (by Business Segment), 2017-2019
  • Figure 11.111: Novartis AG: Net Revenue (by Region), 2017-2019
  • Figure 11.112: Novartis AG: R& D Expense, 2017-2019
  • Figure 11.113: Novartis AG: SWOT Analysis
  • Figure 11.114: Oracle Corporation: Overall Financials, 2017-2019
  • Figure 11.115: Oracle Corporation: Revenue (by Region), 2017-2019
  • Figure 11.116: Oracle Corporation R&D Expenditure, 2017-2019
  • Figure 11.118: Pacific Biosciences of California, Inc.: Overall Product Portfolio
  • Figure 11.119: Pacific Biosciences of California, Inc.: Overall Financials, 2017-2019
  • Figure 11.120: Pacific Biosciences of California, Inc.: Revenue (by Segment), 2017-2019
  • Figure 11.121: Pacific Biosciences of California, Inc.: Revenue (by Region), 2017-2019
  • Figure 11.122: Pacific Biosciences of California, Inc.: R&D Expenditure, 2017-2019
  • Figure 11.123: Pacific Biosciences of California, Inc.: SWOT Analysis
  • Figure 11.124: Partek, Inc.: SWOT Analysis
  • Figure 11.125: Pfizer Inc.: Overall Product Portfolio
  • Figure 11.126: Pfizer Inc.: Overall Financials, 2017-2019
  • Figure 11.127: Pfizer Inc.: Revenue (by Segment), 2017-2019
  • Figure 11.128: Pfizer Inc.: Revenue Split (by Biopharma Segment), 2017-2019
  • Figure 11.129: Pfizer Inc.: Revenue (by Region), 2017-2019
  • Figure 11.130: Pfizer Inc: R&D Expenditure, 2017-2019
  • Figure 11.131: Pfizer Inc.: SWOT Analysis
  • Figure 11.132: QIAGEN N.V.: Portfolio
  • Figure 11.133: QIAGEN N.V.: Overall Financials, 2017-2019
  • Figure 11.134: QIAGEN N.V.: Revenue (by Segment), 2017-2019
  • Figure 11.135: QIAGEN N.V.: Revenue (by Region), 2017-2019
  • Figure 11.136: QIAGEN N.V.: R&D Expenditure, 2017-2019
  • Figure 11.137: QIAGEN N.V.: SWOT Analysis
  • Figure 11.138: Quest Diagnostics Incorporated: Overall Financials, 2017-2019
  • Figure 11.139: Quest Diagnostics Incorporated: SWOT Analysis
  • Figure 11.140: Randox Laboratories Ltd.: SWOT Analysis
  • Figure 11.141: Sanofi SA: Product Portfolio
  • Figure 11.142: Sanofi SA: Overall Financials, 2017-2019
  • Figure 11.143: Sanofi SA: Revenue (by Segment), 2017-2019
  • Figure 11.144: Sanofi SA: Revenue (by Region), 2017-2019
  • Figure 11.145: Sanofi SA: R&D Expenditure, 2017-2019
  • Figure 11.146: Sanofi SA: SWOT Analysis
  • Figure 11.147: Sysmex Corporation: Overall Financials, 2017-2019
  • Figure 11.148: Sysmex Corporation: Revenue (by Business Segment), 2018-2019
  • Figure 11.149: Sysmex Corporation R&D Expenditure, 2017-2019
  • Figure 11.150: Sysmex Corporation: SWOT Analysis
  • Figure 11.151: Teva Pharmaceuticals Industries Ltd.: Product Portfolio
  • Figure 11.152: Teva Pharmaceuticals Industries Ltd.: Overall Financials, 2017-2019
  • Figure 11.153: Teva Pharmaceuticals Industries Ltd.: Revenue (by Region), 2017-2019
  • Figure 11.154: Teva Pharmaceuticals Industries Ltd. R&D Expenditure, 2017-2019
  • Figure 11.155: Teva Pharmaceuticals Industries Ltd.: SWOT Analysis
  • Figure 11.156: Thermo Fisher Scientific Inc.: Product Portfolio
  • Figure 11.157: Thermo Fisher Scientific Inc.: Overall Financials, 2017-2019
  • Figure 11.158: Thermo Fisher Scientific Inc.: Revenue (by Segment), 2017-2019
  • Figure 11.159: Thermo Fisher Scientific Inc.: Revenue (by Region), 2017-2019
  • Figure 11.160: Thermo Fisher Scientific Inc.: R&D Expenditure, 2017-2019
  • Figure 11.161: Thermo Fisher Scientific Inc.: SWOT Analysis

List of Tables

  • Table 4.1: Initiatives and Programs
  • Table 5.1: Percentage of Total Regional Aged Population (65 years & above: 2015 & 2030)
  • Table 5.2: Estimated Number of Cancer Incident Cases for 2018 and 2040
  • Table 5.3: Policy and Guidance Documents from the U.S. FDA
  • Table 6.1: Pipeline Analysis (by Company)
  • Table 6.2: Pipeline Analysis (by Product)
  • Table 6.3: Precision Medicine Drugs Pipeline Analysis
  • Table 8.1: List of Few FDA Approved Pharmacogenomics Biomarkers in Drug Labeling
  • Table 8.2: Key Approved Therapeutics with FDA-Mandated Companion Diagnostics Tests
  • Table 8.3: List of FDA Approved Companion Diagnostics
  • Table 8.4: Commercially Available Primary and Secondary Analysis Tools Providers
  • Table 9.1: Cancer Precision Medicine Drugs and Indications
  • Table 9.2: Infectious Diseases Precision Medicine Drugs and Indications
  • Table 9.3: Neurology Precision Medicine Drugs and Indications
  • Table 9.4: Cardiovascular Precision Medicine Drugs/Tests/ and Indications
  • Table 9.5: Endocrinology Precision Medicine Drugs and Indications
  • Table 9.6: Gastroenterology Precision Medicine Drugs and Indications
  • Table 9.7: Precision Drugs for Other Applications
  • Table 10.1: Funding scenario in Universities

"Global Precision Medicine Market to Reach $278.61 Billion by 2030."

Market Report Coverage - Precision Medicine

Market Segmentation

  • By Ecosystem: Applied Sciences, Precision Diagnostics, Precision Therapeutics, Digital Health and IT
  • By Application: Cancer, Infectious Disease, Neurology, Cardiovascular, Endocrinology, Gastroenterology and Other Applications
  • By Region: North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World

Cross Segmentation

  • Applied Sciences: By Product, By Technology, By End User, By Region
  • Precision Diagnostics: By Product, By Technology, By End User, By Region
  • Precision Therapeutics: By Product, By Technology, By End User, By Region
  • Digital Health and IT: By Product, By Technology, By End User, By Region

Regional Segmentation

  • North America: U.S. and Canada
  • Europe: Germany, France, U.K., Italy, Spain, and Rest-of-Europe
  • Asia-Pacific: Japan, China, India, Australia, and Rest-of-Asia-Pacific
  • Latin America: Brazil, Mexico, and Rest-of-Latin America
  • Rest-of-the-World

Growth Drivers

  • Advancement of Sequencing Technologies
  • Rising Prevalence of Chronic Diseases
  • Growing Demand for Preventive Care
  • Shifting the Significance in Medicine from Reaction to Prevention
  • Reducing Adverse Drug Reactions Through Pharmacogenomics Test
  • Potential to Reduce the Overall Healthcare Cost Across the Globe

Market Challenges

  • Unified Framework for Data Integration
  • Limited Knowledge about Molecular Mechanism/ Interaction
  • Lack of Robust Reimbursement Landscape
  • Regulatory Hurdles

Market Opportunities

  • Targeted Gene Therapy
  • Expansion into the Emerging Markets
  • Collaborations and Partnerships Across Value Chain to Accelerate the Market Entry

Key Companies Profiled

Abbott Laboratories, Almac Group Ltd, Amgen Inc., ANGLE plc, Astellas Pharma Inc., Astra Zeneca PLC, ASURAGEN INC., Bio-Rad Laboratories, Inc., bioMerieux SA., Bristol-Myers Squibb Company, Cardiff Oncology, CETICS Healthcare Technologies GmbH, Danaher Corporation, Eli Lilly and Company Limited, Epic Sciences, Inc., F. Hoffmann-La Roche Ltd, GE Corporation, Gilead Sciences, Inc., GlaxoSmithKline Plc, Illumina, Inc., Intomics A/S, Johnson & Johnson Company, Konica Minolta, Inc., Laboratory Corporation of America, MDx Health, Inc., Menarini Silicon Biosystems, Inc., Merck KGaA, Myriad Genetics, Inc., Novartis AG, Oracle Corporation, Partek, Inc., Pfizer, Inc., QIAGEN N.V., Quest Diagnostics Inc, Randox Laboratories Ltd., Sanofi S.A., Sysmex Corporation, Teva Pharmaceuticals Industries Ltd., Thermo Fisher Scientific, Inc.

Key Questions Answered in this Report:

  • What are the estimated and projected numbers for the global precision medicine market for 2020 and 2030?
  • What are the drivers, challenges, and opportunities that are influencing the dynamics of the market?
  • What is the competition layout of the market?
  • What are the parameters on which competition mapping is carried out in the study?
  • Which key development strategies are being followed and implemented by major players to help them sustain in the market?
  • How are different segments of the market expected to perform during the forecast period from 2020 to 2030? The segments included in the comprehensive market study are:
    • product type
    • region
    • technology
    • application
  • Which leading players are currently dominating the marke,t and what is the expected future scenario?
  • Which companies are anticipated to be highly disruptive in the future, and why?
  • How can the changing dynamics of the market impact the market share of different players operating in the market?
  • What are the strategic recommendations offered in the study?

Market Overview

Precision medicine refers to the medicine developed as per an individual's genetic profile. It provides guidance regarding the prevention, diagnosis, and treatment of diseases. The segmentation of the population is done depending on the genome structure of the individuals and their compatibility with a specific drug molecule. In the precision medicine market, the application of molecular biology is to study the cause of a patient's disease at the molecular level, so that target-based therapies or individualized therapies can be applied to cure the patient's health-related problems. This industry is gaining traction due to the increasing awareness about healthcare among individuals, integration of smart devices such as smartphones and tablets into healthcare, and increasing collaborations and agreements of IT firms with the diagnostics and biopharmaceutical companies for the development of precision diagnostic tools.

The current precision medicine market is mainly dominated by several majors, such as Abbott Laboratories, Almac Group Ltd, Amgen Inc., ANGLE plc, Astellas Pharma Inc, Astra Zeneca PLC, ASURAGEN INC., Bio-Rad Laboratories, Inc., bioMerieux SA., Bristol-Myers Squibb Company, Cardiff Oncology, CETICS Healthcare Technologies GmbH, Danaher Corporation, Eli Lilly and Company Limited, Epic Sciences, Inc., F. Hoffmann-La Roche Ltd, GE Corporation, Gilead Sciences, Inc., GlaxoSmithKline Plc, Illumina, Inc. Intomics A/S, and Johnson & Johnson Company, Konica Minolta, Inc.

Within the research report, the market is segmented on the basis of product type, ecosystem application, and region, which highlight value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, future opportunities, among others, to detail the scope and provide 360-degree coverage of the domain.

Competitive Landscape

Major players, such as Abbott Laboratories, Almac Group Ltd, Amgen Inc., ANGLE plc, Astellas Pharma Inc, Astra Zeneca PLC, ASURAGEN INC., Bio-Rad Laboratories, Inc., bioMerieux SA., Bristol-Myers Squibb Company, Cardiff Oncology, CETICS Healthcare Technologies GmbH, Danaher Corporation, Eli Lilly and Company Limited, Epic Sciences, Inc., F. Hoffmann-La Roche Ltd, GE Corporation, Gilead Sciences, Inc., GlaxoSmithKline Plc, Illumina, Inc., Intomics A/S, Johnson & Johnson Company, Konica Minolta, Inc., Laboratory Corporation of America MDx Health, Inc., Menarini Silicon Biosystems, Inc., Merck & Co., Inc., Myriad Genetics, Inc., Novartis AG., Oracle Corporation, Partek, Inc., Pfizer, Inc., QIAGEN N.V., Quest Diagnostics Inc., Randox Laboratories Ltd., Sanofi SA, Sysmex Corporation, Teva Pharmaceuticals Industries Ltd., Thermo Fisher Scientific, Inc. including among others, led the number of key developments witnessed by the market. On the basis of region, North America is expected to retain a leading position throughout the forecast period 2020-2030, followed by Europe.

Table of Contents

1. Product Definition

  • 1.1. Inclusion and Exclusion

2. Research Scope

  • 2.1. Scope of Study
  • 2.2. Key Questions Answered in the Report
  • 2.3. Global Precision Medicine Market: Research Methodology
  • 2.4. Criteria for Company Profiling

3. Research Methodology

  • 3.1. Primary Data Sources
  • 3.2. Secondary Data Sources
  • 3.3. Market Estimation Model

4. Global Precision Medicine Market Overview

  • 4.1. Market Definition
  • 4.2. Precision Medicine: A Frontier in the Genesis of Patient-centric Medicine
  • 4.3. Precision Medicine: Remodeling the One-Size-Fits-All Theory to Individually Tailored Therapy
  • 4.4. Initiatives and Programs
  • 4.5. Precision Medicine: Enabling Technologies and Applications
    • 4.5.1. Innovators
      • 4.5.1.1. 3D DNA Printing
        • 4.5.1.1.1. Introduction
        • 4.5.1.1.2. Role of 3D DNA Printing
      • 4.5.1.2. RNA-Seq
        • 4.5.1.2.1. Introduction
        • 4.5.1.2.2. Role of RNA-Seq in Precision Medicine
        • 4.5.1.2.3. Key Players
      • 4.5.1.3. 4D Molecular Imaging
        • 4.5.1.3.1. Introduction
        • 4.5.1.3.2. Role of 4D Molecular Imaging in Precision Medicine
        • 4.5.1.3.3. Key Players
    • 4.5.2. Early Adopters
      • 4.5.2.1. CRISPR
        • 4.5.2.1.1. Introduction
        • 4.5.2.1.2. Role of CRISPR in Precision Medicine
        • 4.5.2.1.3. Key Players
      • 4.5.2.2. Blockchain
        • 4.5.2.2.1. Introduction
        • 4.5.2.2.2. Role of Blockchain in Precision Medicine
        • 4.5.2.2.3. Key Players
      • 4.5.2.3. Imaging Informatics
        • 4.5.2.3.1. Introduction
        • 4.5.2.3.2. Role of Imaging Informatics in Precision Medicine
        • 4.5.2.3.3. Key Players
    • 4.5.3. Early Majority
      • 4.5.3.1. Artificial Intelligence (AI)
        • 4.5.3.1.1. Introduction
        • 4.5.3.1.2. Role of Artificial Intelligence in Precision Medicine
        • 4.5.3.1.3. Key Players
      • 4.5.3.2. Circulating Free DNA (cfDNA)
        • 4.5.3.2.1. Introduction
        • 4.5.3.2.2. Role of cfDNA in Precision Medicine
        • 4.5.3.2.3. Key Players
      • 4.5.3.3. Big Data
        • 4.5.3.3.1. Introduction
        • 4.5.3.3.2. Role of Big Data in Precision Medicine
        • 4.5.3.3.3. Key Players
      • 4.5.3.4. Next-Generation Sequencing (NGS)
        • 4.5.3.4.1. Introduction
        • 4.5.3.4.2. Role of NGS in Precision Medicine
        • 4.5.3.4.3. Key Players
      • 4.5.3.5. Health Informatics
        • 4.5.3.5.1. Introduction
        • 4.5.3.5.2. Role of Health Informatics in Precision Medicine
        • 4.5.3.5.3. Key players
      • 4.5.3.6. Bioinformatics
        • 4.5.3.6.1. Introduction
        • 4.5.3.6.2. Role of Bioinformatics in Precision Medicine
        • 4.5.3.6.3. Key Players
    • 4.5.4. Late Majority
      • 4.5.4.1. Polymerase Chain Reactions (PCR)
        • 4.5.4.1.1. Introduction
        • 4.5.4.1.2. Role of PCR in Precision Medicine
        • 4.5.4.1.3. Key players
      • 4.5.4.2. Microarray
        • 4.5.4.2.1. Role of Microarray in Precision Medicine
        • 4.5.4.2.2. Key Players
  • 4.6. COVID-19 Impact on the Global Precision Medicine Market

5. Market Dynamics

  • 5.1. Overview
  • 5.2. Market Drivers
    • 5.2.1. Advancement of Sequencing Technologies
    • 5.2.2. Rising Prevalence of Chronic Diseases
    • 5.2.3. Growing Demand for Preventive Care
    • 5.2.4. Shifting the Significance in Medicine, from Reaction to Prevention
    • 5.2.5. Reducing Adverse Drug Reactions Through Pharmacogenomics Test
    • 5.2.6. Potential to Reduce the Overall Healthcare Cost Across the Globe
  • 5.3. Market Restraints
    • 5.3.1. Unified Framework for Data Integration
    • 5.3.2. Limited Knowledge about Molecular Mechanism/ Interaction
    • 5.3.3. Lack of Robust Reimbursement Landscape
    • 5.3.4. Regulatory Hurdles
  • 5.4. Market Opportunities
    • 5.4.1. Targeted Gene Therapy
    • 5.4.2. Expansion into the Emerging Markets
    • 5.4.3. Collaboration and Partnerships Across Value Chain to Accelerate the Market Entry

6. Industry Insights

  • 6.1. Patent Analysis
  • 6.2. Legal Requirements and Regulations
  • 6.3. Pipeline Analysis
  • 6.4. Legal Requirements and Framework by the FDA
  • 6.5. Legal Requirements and Framework by the EMA
  • 6.6. Legal Requirements and Framework by the MHLW

7. Competitive Landscape

  • 7.1. Synergistic Activities
    • 7.1.1. Product launches, Enhancements, and Upgradation
    • 7.1.2. Product Approvals
    • 7.1.3. Mergers and Acquisitions
    • 7.1.4. Business Expansion
  • 7.2. Market Share Analysis
    • 7.2.1. Market Share Analysis by Applied Sciences, 2019
    • 7.2.2. Market Share Analysis by Precision Diagnostics, 2019
    • 7.2.3. Market Share Analysis by Precision Therapeutics, 2019
    • 7.2.4. Market Share Analysis by Digital Health and IT, 2019

8. Global Precision Medicine Market (by Ecosystem)

  • 8.1. Overview
  • 8.2. Applied Sciences
    • 8.2.1. Genomics
    • 8.2.2. Global Precision Medicine Genomics Market (by Technology)
      • 8.2.2.1. Polymerase Chain Reaction (PCR)
        • 8.2.2.1.1. Global Precision Medicine PCR Market (by Product)
        • 8.2.2.1.2. Global Precision Medicine PCR Market (by End User)
        • 8.2.2.1.3. Global Precision Medicine PCR Market (by Region)
      • 8.2.2.2. Next-Generation Sequencing (NGS)
        • 8.2.2.2.1. Global Precision Medicine NGS Market (by Product)
        • 8.2.2.2.2. Global Precision Medicine NGS Market (by Technology)
        • 8.2.2.2.3. Global Precision Medicine NGS Market (by End User)
        • 8.2.2.2.4. Global Precision Medicine NGS Market (by Region)
      • 8.2.2.3. Genome Editing
        • 8.2.2.3.1. Global Precision Medicine Genome Editing Market (by Product)
        • 8.2.2.3.2. Global Precision Medicine Genome Editing Market (by End User)
        • 8.2.2.3.3. Global Precision Medicine Genome Editing Market (by Region)
      • 8.2.2.4. Other Technologies
        • 8.2.2.4.1. Global Precision Medicine Other Technologies Market (by Region)
    • 8.2.3. Pharmacogenomics
      • 8.2.3.1. Global Precision Medicine Pharmacogenomics Market (by Pharmacogenomics Services)
      • 8.2.3.2. Global Precision Medicine Pharmacogenomics Market (by End User)
      • 8.2.3.3. Global Precision Medicine Pharmacogenomics Market (by Region)
    • 8.2.4. Other Applied Sciences
  • 8.3. Precision Diagnostics
    • 8.3.1. Molecular Diagnostics (MDx)
    • 8.3.2. Global Precision Medicine Molecular Diagnostics Market (by Type)
      • 8.3.2.1. Non-Invasive Prenatal Testing (NIPT)
        • 8.3.2.1.1. Global Precision Medicine NIPT Market (by Platform)
        • 8.3.2.1.2. Global Precision Medicine NIPT Market (by Region)
      • 8.3.2.2. Companion Diagnostics
        • 8.3.2.2.1. Global Precision Medicine Companion Diagnostics Market (by Technology)
        • 8.3.2.2.2. Global Precision Medicine Companion Diagnostics Market (by Indication)
        • 8.3.2.2.3. Global Precision Medicine Companion Diagnostics Market (by Region)
      • 8.3.2.3. Liquid Biopsy
        • 8.3.2.3.1. Global Precision Medicine Liquid Biopsy Market (by Indication)
        • 8.3.2.3.2. Global Precision Medicine Liquid Biopsy Market (by Region)
      • 8.3.2.4. Other Molecular Diagnostics
        • 8.3.2.4.1. Global Precision Medicine Other Molecular Diagnostics Market (by Type)
        • 8.3.2.4.2. Global Precision Medicine Other Molecular Diagnostics Market (by Region)
    • 8.3.3. Medical Imaging
      • 8.3.3.1. Global Precision Medicine Medical Imaging Market (by Type)
        • 8.3.3.1.1. Imaging Analytics
        • 8.3.3.1.2. Imaging Computer-Aided Detection (CADx)
      • 8.3.3.2. Global Precision Medicine Medical Imaging Market (by Region)
  • 8.4. Digital Health and Information Technology
    • 8.4.1. Global Precision Medicine Digital Health and Information Technology Market (by Type)
      • 8.4.1.1. Clinical Decision Support Systems (CDSS)
      • 8.4.1.2. Big Data Analytics
      • 8.4.1.3. IT Infrastructure
        • 8.4.1.3.1. Global Precision Medicine IT Infrastructure Market (by Type)
      • 8.4.1.4. Genomics Informatics
        • 8.4.1.4.1. Global Precision Medicine Genomics Informatics Market (by Product Type)
      • 8.4.1.5. In-Silico Informatics
      • 8.4.1.6. Mobile Health
    • 8.4.2. Global Precision Medicine Digital Health and Information Technology Market (by End User)
    • 8.4.3. Global Precision Medicine Digital Health and Information Technology Market, (by Region)
  • 8.5. Precision Therapeutics
    • 8.5.1. Global Precision Medicine Therapeutics Market (by Type)
      • 8.5.1.1. Clinical Trials
        • 8.5.1.1.1. Global Precision Medicine Clinical Trials Market (by Region)
      • 8.5.1.2. Cell Therapy
        • 8.5.1.2.1. Global Precision Medicine Cell Therapy Market (by Region)
      • 8.5.1.3. Drug Discovery and Research
        • 8.5.1.3.1. Global Precision Medicine Drug Discovery and Research Market (by Region),
      • 8.5.1.4. Gene Therapy
        • 8.5.1.4.1. Global Precision Medicine Drug Discovery and Research Market (by Region)

9. Global Precision Medicine Market (by Application)

  • 9.1. Overview
  • 9.2. Oncology
    • 9.2.1. Cancer Precision Medicine Drugs and Indications
  • 9.3. Infectious Diseases
    • 9.3.1. Infectious Diseases Precision Medicine Drugs and Indications
  • 9.4. Neurology
    • 9.4.1. Neurology Precision Medicine Drugs and Indications
  • 9.5. Cardiovascular
    • 9.5.1. Cardiovascular Precision Medicine Drugs/Tests/ and Indications
  • 9.6. Lifestyle and Endocrinology
    • 9.6.1. Endocrinology Precision Medicine Drugs and Indications
  • 9.7. Gastroenterology
    • 9.7.1. Gastroenterology Precision Medicine Drugs and Indications
  • 9.8. Other Applications
    • 9.8.1. Precision Drugs for Other Applications

10. Global Precision Medicine Market, (by Region)

  • 10.1. Overview
  • 10.2. North America
    • 10.2.1. North America Precision Medicine Market (by Ecosystem)
    • 10.2.2. U.S.
      • 10.2.2.1. Overview of Precision Medicine
      • 10.2.2.2. Key Trends
      • 10.2.2.3. Promoting Factors
      • 10.2.2.4. Recent Key Developments
      • 10.2.2.5. Funding Scenario/Investments
      • 10.2.2.6. Regulatory Scenario
      • 10.2.2.7. Key Players
    • 10.2.3. Canada
      • 10.2.3.1. Overview of Precision Medicine
      • 10.2.3.2. Key Trends
      • 10.2.3.3. Promoting Factors
      • 10.2.3.4. Recent Key Developments
      • 10.2.3.5. Regulatory Scenario
      • 10.2.3.6. Key Players
  • 10.3. Europe
    • 10.3.1. Europe Precision Medicine Market (by Ecosystem)
    • 10.3.2. Germany
      • 10.3.2.1. Overview of Precision Medicine
      • 10.3.2.2. Key Trends
      • 10.3.2.3. Promoting Factors
      • 10.3.2.4. Recent Key Developments
      • 10.3.2.5. Key Players
    • 10.3.3. France
      • 10.3.3.1. Overview of Precision Medicine
      • 10.3.3.2. Key Trends
      • 10.3.3.3. Promoting Factors
      • 10.3.3.4. Recent Key Developments
      • 10.3.3.5. Key Players
    • 10.3.4. Italy
      • 10.3.4.1. Overview of Precision Medicine
      • 10.3.4.2. Key Trends
      • 10.3.4.3. Promoting Factors
      • 10.3.4.4. Recent Key Developments
      • 10.3.4.5. Funding Scenario/Investments
    • 10.3.5. U.K.
      • 10.3.5.1. Overview of Precision Medicine
      • 10.3.5.2. Key Trends
      • 10.3.5.3. Promoting Factors
      • 10.3.5.4. Recent Key Developments
      • 10.3.5.5. Funding Scenario/Investments
      • 10.3.5.6. Key Players
    • 10.3.6. Spain
      • 10.3.6.1. Overview of Precision Medicine
      • 10.3.6.2. Key Trends
      • 10.3.6.3. Promoting Factors
      • 10.3.6.4. Recent Key Developments
      • 10.3.6.5. Key Players
    • 10.3.7. Rest-of-Europe
      • 10.3.7.1. Switzerland
  • 10.4. Asia-Pacific
    • 10.4.1. Asia-Pacific Precision Medicine Market (by Ecosystem)
    • 10.4.2. China
      • 10.4.2.1. Overview of Precision Medicine
      • 10.4.2.2. Key Trends
      • 10.4.2.3. Promoting Factors
      • 10.4.2.4. Recent Key Developments
      • 10.4.2.5. Key Players
    • 10.4.3. Japan
      • 10.4.3.1. Overview of Precision Medicine
      • 10.4.3.2. Key Trends
      • 10.4.3.3. Promoting Factors
      • 10.4.3.4. Recent Key Developments
      • 10.4.3.5. Reimbursement Scenario
      • 10.4.3.6. Key Players
    • 10.4.4. Australia
      • 10.4.4.1. Overview of Precision Medicine
      • 10.4.4.2. Key Trends
      • 10.4.4.3. Promoting Factors
      • 10.4.4.4. Recent Key Developments
      • 10.4.4.5. Regulatory Scenario
      • 10.4.4.6. Key Players
    • 10.4.5. India
      • 10.4.5.1. Overview of Precision Medicine
      • 10.4.5.2. Key Trends
      • 10.4.5.3. Promoting Factors
      • 10.4.5.4. Recent Key Developments
      • 10.4.5.5. Key Players
    • 10.4.6. Rest-of-Asia-Pacific (RoAPAC)
      • 10.4.6.1. Singapore
        • 10.4.6.1.1. Regulatory Framework
      • 10.4.6.2. South Korea
      • 10.4.6.3. Vietnam
  • 10.5. Latin America
    • 10.5.1. Latin America Precision Medicine Market (by Ecosystem)
    • 10.5.2. Brazil
      • 10.5.2.1. Overview of Precision Medicine
    • 10.5.3. Mexico
      • 10.5.3.1. Overview of Precision Medicine
      • 10.5.3.2. Recent Key Developments
    • 10.5.4. Rest-of-Latin America (RoLA)
  • 10.6. Rest-of-the-World (RoW)
    • 10.6.1. Rest-of-the-World Precision Medicine Market (by Ecosystem)
      • 10.6.1.1. Israel
      • 10.6.1.2. Saudi Arabia
      • 10.6.1.3. United Arab Emirates
      • 10.6.1.4. South Africa
      • 10.6.1.5. Russia

11. Company Profiles

  • 11.1. Overview
  • 11.2. Abbott Laboratories
    • 11.2.1. Company Overview
    • 11.2.2. Role of Abbott Laboratories in Global Precision Medicine Market
    • 11.2.3. Financials
    • 11.2.4. Key Insights About Financial Health of the Company
    • 11.2.5. SWOT Analysis
  • 11.3. Almac Group Ltd.
    • 11.3.1. Company Overview
    • 11.3.2. Role of Almac Group Ltd. in Global Precision Medicine Market
    • 11.3.3. SWOT Analysis
  • 11.4. Amgen Inc.
    • 11.4.1. Company Overview
    • 11.4.2. Role of Amgen Inc. in Global Precision Medicine Market
    • 11.4.3. Financials
    • 11.4.4. Key Insights about Financial Health of the Company
    • 11.4.5. SWOT Analysis
  • 11.5. ANGLE plc
    • 11.5.1. Company Overview
    • 11.5.2. Role of ANGLE plc in Global Precision Medicine Market
    • 11.5.3. Financials
    • 11.5.4. Key Insights about Financial Health of the Company
    • 11.5.5. SWOT Analysis
  • 11.6. Astellas Pharma Inc.
    • 11.6.1. Company Overview
    • 11.6.2. Role of Astellas Pharma Inc.in Global Precision Medicine Market
    • 11.6.3. Financials
    • 11.6.4. Key Insights about Financial Health of the Company
    • 11.6.5. SWOT Analysis
  • 11.7. Astra Zeneca
    • 11.7.1. Company Overview
    • 11.7.2. Role of Astra Zeneca in Global Precision Medicine Market
    • 11.7.3. Financials
    • 11.7.4. SWOT Analysis
  • 11.8. ASURAGEN INC.
    • 11.8.1. Company Overview
    • 11.8.2. Role of ASURAGEN Inc. in Global Precision Medicine Market
    • 11.8.3. SWOT Analysis
  • 11.9. Bio-Rad Laboratories, Inc.
    • 11.9.1. Company Overview
    • 11.9.2. Role of Bio-Rad Laboratories, Inc. in Global Precision Medicine Market
    • 11.9.3. Financials
    • 11.9.4. SWOT Analysis
  • 11.1. bioMérieux S.A.
    • 11.10.1. Company Overview
    • 11.10.2. Role of bioMérieux SA. in Global Precision Medicine Market
    • 11.10.3. Financials
    • 11.10.4. SWOT Analysis
  • 11.11. Bristol-Myers Squibb Company
    • 11.11.1. Company Overview
    • 11.11.2. Role of Bristol-Myers Squibb Company in Global Precision Medicine Market
    • 11.11.3. Financials
    • 11.11.4. Key Insights about Financial Health of the Company
    • 11.11.5. SWOT Analysis
  • 11.12. Cardiff Oncology
    • 11.12.1. Company Overview
    • 11.12.2. Role of Cardiff Oncology in Global Precision Medicine Market
    • 11.12.3. Financials
    • 11.12.4. Key Insights About Financial Health of the Company
    • 11.12.5. SWOT Analysis
  • 11.13. CETICS Healthcare Technologies GmbH
    • 11.13.1. Company Overview
    • 11.13.2. Role CETICS Healthcare Technologies GmbH in Global Precision Medicine Market
    • 11.13.3. SWOT Analysis
  • 11.14. Danaher Corporation
    • 11.14.1. Company Overview
    • 11.14.2. Role of Danaher Corporation in Global Precision Medicine Market
    • 11.14.3. Financials
    • 11.14.4. SWOT Analysis
  • 11.15. Eli Lilly and Company Limited
    • 11.15.1. Company Overview
    • 11.15.2. Role of Eli Lilly and Company Limited in Global Precision Medicine Market
    • 11.15.3. Financials
    • 11.15.4. SWOT Analysis
  • 11.16. Epic Sciences, Inc.
    • 11.16.1. Company Overview
    • 11.16.2. Role Epic Sciences, Inc. in Global Precision Medicine Market
    • 11.16.3. SWOT Analysis
  • 11.17. F. Hoffmann-La Roche Ltd
    • 11.17.1. Company Overview
    • 11.17.2. Role of F. Hoffman-LA Roche Ltd in Global Precision Medicine Market
    • 11.17.3. Financials
    • 11.17.4. Key Insights About Financial Health of the Company
    • 11.17.5. SWOT Analysis
  • 11.18. General Electric Company
    • 11.18.1. Company Overview
    • 11.18.2. Role of GE Corporation in Global Precision Medicine Market
    • 11.18.3. Financials
    • 11.18.4. Key Insights about Financial Health of the Company
    • 11.18.5. SWOT Analysis
  • 11.19. Gilead Sciences, Inc.
    • 11.19.1. Company Overview
    • 11.19.2. Role of Gilead Sciences, Inc. in Global Precision Medicine Market
    • 11.19.3. SWOT Analysis
  • 11.2. GlaxoSmithKline plc
    • 11.20.1. Company Overview
    • 11.20.2. Role of GlaxoSmithKline Plc in Global Precision Medicine Market
    • 11.20.3. Financials
    • 11.20.4. Key Insights about Financial Health of the Company
    • 11.20.5. SWOT Analysis
  • 11.21. Illumina, Inc.
    • 11.21.1. Company Overview
    • 11.21.2. Role of Illumina, Inc. in Global Precision Medicine Market
    • 11.21.3. Financials
    • 11.21.4. Key Insights About Financial Health of the Company
    • 11.21.5. SWOT Analysis
  • 11.22. Intomics A/S
    • 11.22.1. Company Overview
    • 11.22.2. Role Intomics A/S in Global Precision Medicine Market
    • 11.22.3. SWOT Analysis
  • 11.23. Johnson & Johnson Services, Inc.
    • 11.23.1. Company Overview
    • 11.23.2. Role of Johnson and Johnson in Global Precision Medicine Market
    • 11.23.3. Financials
    • 11.23.4. Key Insights about Financial Health of the Company
    • 11.23.5. SWOT Analysis
  • 11.24. Konica Minolta, Inc.
    • 11.24.1. Company Overview
    • 11.24.2. Role of Konica Minolta, Inc. in Global Precision Medicine Market
    • 11.24.3. Financials
    • 11.24.4. SWOT Analysis
  • 11.25. Laboratory Corporation of America Holdings
    • 11.25.1. Company Overview
    • 11.25.2. Role of Laboratory Corporation of America Holdings in Global Precision Medicine Market
    • 11.25.3. Financials
    • 11.25.4. SWOT Analysis
  • 11.26. MDx Health, Inc.
    • 11.26.1. Company Overview
    • 11.26.2. Role of MDx Health, Inc. in Global Precision Medicine Market
    • 11.26.3. Financials
    • 11.26.4. SWOT Analysis
  • 11.27. Menarini Silicon Biosystems, Inc.
    • 11.27.1. Company Overview
    • 11.27.2. Role Menarini Silicon Biosystems, Inc. in Global Precision Medicine Market
    • 11.27.3. SWOT Analysis
  • 11.28. Merck KGaA
    • 11.28.1. Company Overview
    • 11.28.2. Role of Merck KGaA in Global Precision Medicine Market
    • 11.28.3. Financials
    • 11.28.4. Key Insights About Financial Health of the Company
    • 11.28.5. SWOT Analysis
  • 11.29. Myriad Genetics, Inc.
    • 11.29.1. Company Overview
    • 11.29.2. Role of Myriad Genetics, Inc. in Global Precision Medicine Market
    • 11.29.3. Financials
    • 11.29.4. Key Insights About Financial Health of the Company
    • 11.29.5. SWOT Analysis
  • 11.3. Novartis AG
    • 11.30.1. Company overview
    • 11.30.2. Role of Novartis AG in Global Precision Medicine Market
    • 11.30.3. Financials
    • 11.30.4. Key Insights about Financial Health of the Company
    • 11.30.5. SWOT Analysis
  • 11.31. Oracle Corporation.
    • 11.31.1. Company Overview
    • 11.31.2. Role of Oracle Corporation in Global Precision Medicine Market
    • 11.31.3. Financials
    • 11.31.4. Key Insights about Financial Health of the Company
    • 11.31.5. SWOT Analysis
  • 11.32. Pacific Biosciences of California, Inc.
    • 11.32.1. Company Overview
    • 11.32.2. Role of Pacific Biosciences of California, Inc. in Global Precision Medicine Market
    • 11.32.3. Financials
    • 11.32.4. Key Insights About Financial Health of the Company
    • 11.32.5. SWOT Analysis
  • 11.33. Partek, Inc.
    • 11.33.1. Company Overview
    • 11.33.2. Role Partek, Inc. in Global Precision Medicine Market
    • 11.33.3. SWOT Analysis
  • 11.34. Pfizer Inc.
    • 11.34.1. Company Overview
    • 11.34.2. Role of Pfizer, Inc. in Global Precision Medicine Market
    • 11.34.3. Financials
    • 11.34.4. Key Insights about Financial Health of the Company
    • 11.34.5. SWOT Analysis
  • 11.35. QIAGEN N.V.*
    • 11.35.1. Company Overview
    • 11.35.2. Role of QIAGEN N.V. in Global Precision Medicine Market
    • 11.35.3. Financials
    • 11.35.4. Key Insights About Financial Health of the Company
    • 11.35.5. SWOT Analysis
  • 11.36. Quest Diagnostics Incorporated
    • 11.36.1. Company Overview
    • 11.36.2. Role of Quest Diagnostics Incorporated in Global Precision Medicine Market
    • 11.36.3. Financials
    • 11.36.4. SWOT Analysis
  • 11.37. Randox Laboratories Ltd.
    • 11.37.1. Company Overview
    • 11.37.2. Role of Randox Laboratories Ltd. in Global Precision Medicine Market
    • 11.37.3. SWOT Analysis
  • 11.38. Sanofi S.A.
    • 11.38.1. Company Overview
    • 11.38.2. Role of Sanofi SA in Global Precision Medicine Market
    • 11.38.3. Financials
    • 11.38.4. Key Insights about Financial Health of the Company
    • 11.38.5. SWOT Analysis
  • 11.39. Sysmex Corporation
    • 11.39.1. Company Overview
    • 11.39.2. Role of Sysmex Corporation in Global Precision Medicine Market
    • 11.39.3. Financials
    • 11.39.4. Key Insights about Financial Health of the Company
    • 11.39.5. SWOT Analysis
  • 11.4. Teva Pharmaceuticals Industries Ltd.
    • 11.40.1. Company Overview
    • 11.40.2. Role of Teva Pharmaceuticals Industries Ltd. in Global Precision Medicine Market
    • 11.40.3. Financials
    • 11.40.4. Key Insights about Financial Health of the Company
    • 11.40.5. SWOT Analysis
  • 11.41. Thermo Fisher Scientific Inc.
    • 11.41.1. Company Overview
    • 11.41.2. Role of Thermo Fisher Scientific Inc. in Global Precision Medicine Market
    • 11.41.3. Financials
    • 11.41.4. Key Insights About Financial Health of the Company
    • 11.41.5. SWOT Analysis
Back to Top
전화 문의
F A Q